Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 35 out of 100. Drug development

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

Senile plaques and neurofibrillary tangles are the markers of Alzheimer's disease. They are also found in old patients who have been considered to be intellectually normal throughout their life, a situation referred to as "physiological aging". The neurofibrillary tangles are made of abnormally phosphorylated tau.

What this study adds

Evidence grade: Low

This is a narrative review. This prospective clinicopathological study describes senile plaques and neurofibrillary tangles as markers of Alzheimer's disease that are also found in some intellectually normal older people, referred to as physiological aging. It describes the progression of lesions rather than reporting a treatment, cure or prevention.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Duyckaerts, C., Colle, M. A., Dessi, F., Grignon, Y., Piette, F., & Hauw, J. J. (1998). The progression of the lesions in Alzheimer disease: insights from a prospective clinicopathological study. Journal of neural transmission. Supplementum. https://doi.org/10.1007/978-3-7091-6467-9_10

Vancouver

Duyckaerts C, Colle MA, Dessi F, Grignon Y, Piette F, Hauw JJ. The progression of the lesions in Alzheimer disease: insights from a prospective clinicopathological study. Journal of neural transmission. Supplementum. 1998. doi:10.1007/978-3-7091-6467-9_10. PMID: 9700650.

BibTeX

@article{duyckaerts1998-9700650,
  author  = {Duyckaerts, C. and Colle, M. A. and Dessi, F. and Grignon, Y. and Piette, F. and Hauw, J. J.},
  title   = {{The progression of the lesions in Alzheimer disease: insights from a prospective clinicopathological study}},
  journal = {Journal of neural transmission. Supplementum},
  year    = {1998},
  doi     = {10.1007/978-3-7091-6467-9_10},
  pmid    = {9700650},
  url     = {https://doi.org/10.1007/978-3-7091-6467-9_10}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

Key findings

Why it matters

This prospective clinicopathological study describes senile plaques and neurofibrillary tangles as markers of Alzheimer's disease that are also found in some intellectually normal older people, referred to as physiological aging. It describes the progression of lesions rather than reporting a treatment, cure or prevention.

Study details

How this study scored 35/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record left out, no data; Study design 0 of 12; Strength of evidence 1 of 5; Peer-review validation 10 of 10; How recent 1 of 5; Sample size 0 of 4; Effect reported 0 of 3; Studied in people 0 of 3; Randomized / blinded 0 of 2; Times cited 3 of 7; Citations per year 1 of 5; Impact for its field and year 3 of 6; Cited by studies here 1 of 6; Still being cited 0 of 4; Senior author's track record 3 of 4; Institution's track record 1 of 3; Multicenter collaboration 1 of 3; Indexed in PubMed 2 of 2; Free to read 0 of 2. 34 of the 96 points it could be judged on, which is 35 of 100. Total 35 of 100.34 of the 96 points we could judge = 35 of 100

Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it. We have no data on journal's citation record, so that was left out: it earned 34 of the 96 points we could judge it on, which is 35 out of 100.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Journal of neural transmission. Supplementum)
Journal's citation record — / 4 No journal record from OpenAlex — left out of this score
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 1 / 5 1998 — older than 20 years, still counted
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 0 / 3 Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 3 / 7 Cited 32 times (OpenAlex, 2026-10-10)
Citations per year 1 / 5 1.1 citations a year over 30 year(s) since 1998
Impact for its field and year 3 / 6 Cited 5.8× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 1 / 6 Cited by 2 other studies in this library
Still being cited 0 / 4 Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 3 / 4 Last-listed author Jean‐Jacques Hauw: h-index 81 (OpenAlex, whole career)
Institution's track record 1 / 3 Pitié-Salpêtrière Hospital: institution h-index 837 (OpenAlex)
Multicenter collaboration 1 / 3 OpenAlex lists 2 institution(s) in 1 country
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 9700650)
Free to read 0 / 2 Behind a paywall — scores zero
Points 34 / 96 Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 34 of the 96 points we could judge it on is 35 out of 100.
Total 35 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Later studies that cite this one

2 studies in the alzhub library list this one in their references.

Related studies in Drug development from nearby years

Also in Drug development

107 studies in the library are filed under Drug development with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Drug development hub.

Similar studies

More on Drug development

See all studies in Drug development →